Jill Bargonetti to Tumor Suppressor Protein p53
This is a "connection" page, showing publications Jill Bargonetti has written about Tumor Suppressor Protein p53.
Connection Strength
9.587
-
Ellison V, Polotskaia A, Xiao G, Leybengrub P, Lee R, Qiu W, Hendrickson RC, Hu W, Bargonetti J. A cancer persistent DNA repair circuit driven by MDM2, MDM4 (MDMX), and mutant p53 for recruitment of MDC1 and 53BP1 on chromatin. Nucleic Acids Res. 2025 Jul 08; 53(13).
Score: 0.781
-
Lundine D, Annor GK, Chavez V, Maimos S, Syed Z, Jiang S, Ellison V, Bargonetti J. The C-terminus of Gain-of-Function Mutant p53 R273H Is Required for Association with PARP1 and Poly-ADP-Ribose. Mol Cancer Res. 2022 12 02; 20(12):1799-1810.
Score: 0.652
-
Xiao G, Annor GK, Fung K, Kein?nen O, Zeglis BM, Bargonetti J. Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide. Mol Pharm. 2021 01 04; 18(1):338-346.
Score: 0.568
-
Xiao G, Lundine D, Annor GK, Canar J, Ellison V, Polotskaia A, Donabedian PL, Reiner T, Khramtsova GF, Olopade OI, Mazo A, Bargonetti J. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer. Cancer Res. 2020 02 01; 80(3):394-405.
Score: 0.529
-
Bargonetti J, Prives C. Gain-of-function mutant p53: history and speculation. J Mol Cell Biol. 2019 07 19; 11(7):605-609.
Score: 0.516
-
Loo LWM, Gao C, Shvetsov YB, Okoro DR, Hernandez BY, Bargonetti J. MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population. Breast Cancer Res Treat. 2019 Feb; 174(1):257-269.
Score: 0.493
-
Kundu N, Brekman A, Kim JY, Xiao G, Gao C, Bargonetti J. Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway. Oncotarget. 2017 Jul 18; 8(29):47916-47930.
Score: 0.449
-
Shtraizent N, Matsui H, Polotskaia A, Bargonetti J. Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient. Int J Environ Res Public Health. 2015 Dec 22; 13(1):ijerph13010022.
Score: 0.403
-
Rosso M, Polotskaia A, Bargonetti J. Homozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death. Oncotarget. 2015 Oct 27; 6(33):34573-91.
Score: 0.399
-
Xiao G, Kue P, Bhosle R, Bargonetti J. Decarbamoyl mitomycin C (DMC) activates p53-independent ataxia telangiectasia and rad3 related protein (ATR) chromatin eviction. Cell Cycle. 2015; 14(5):744-54.
Score: 0.377
-
Hoffman S, Martin D, Mel?ndez A, Bargonetti J. C. elegans CEP-1/p53 and BEC-1 are involved in DNA repair. PLoS One. 2014; 9(2):e88828.
Score: 0.355
-
Okoro DR, Arva N, Gao C, Polotskaia A, Puente C, Rosso M, Bargonetti J. Endogenous human MDM2-C is highly expressed in human cancers and functions as a p53-independent growth activator. PLoS One. 2013; 8(10):e77643.
Score: 0.346
-
Polotskaia A, Hoffman S, Krett NL, Shanmugam M, Rosen ST, Bargonetti J. 8-Amino-adenosine activates p53-independent cell death of metastatic breast cancers. Mol Cancer Ther. 2012 Nov; 11(11):2495-504.
Score: 0.321
-
Brekman A, Singh KE, Polotskaia A, Kundu N, Bargonetti J. A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation. Breast Cancer Res. 2011 Jan 11; 13(1):R3.
Score: 0.286
-
Boamah EK, Brekman A, Tomasz M, Myeku N, Figueiredo-Pereira M, Hunter S, Meyer J, Bhosle RC, Bargonetti J. DNA adducts of decarbamoyl mitomycin C efficiently kill cells without wild-type p53 resulting from proteasome-mediated degradation of checkpoint protein 1. Chem Res Toxicol. 2010 Jul 19; 23(7):1151-62.
Score: 0.277
-
Arva NC, Talbott KE, Okoro DR, Brekman A, Qiu WG, Bargonetti J. Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes. Ethn Dis. 2008; 18(2 Suppl 2):S2-1-8.
Score: 0.232
-
Boamah EK, White DE, Talbott KE, Arva NC, Berman D, Tomasz M, Bargonetti J. Mitomycin-DNA adducts induce p53-dependent and p53-independent cell death pathways. ACS Chem Biol. 2007 Jun 15; 2(6):399-407.
Score: 0.222
-
White DE, Talbott KE, Arva NC, Bargonetti J. Mouse double minute 2 associates with chromatin in the presence of p53 and is released to facilitate activation of transcription. Cancer Res. 2006 Apr 01; 66(7):3463-70.
Score: 0.205
-
Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE, Bond GL, Levine AJ, Bargonetti J. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem. 2005 Jul 22; 280(29):26776-87.
Score: 0.193
-
Liu J, Shen Y, Liu J, Xu D, Chang CY, Wang J, Zhou J, Haffty BG, Zhang L, Bargonetti J, De S, Hu W, Feng Z. Lipogenic enzyme FASN promotes mutant p53 accumulation and gain-of-function through palmitoylation. Nat Commun. 2025 Feb 19; 16(1):1762.
Score: 0.190
-
Madorsky Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B, Kyei I, Aitpillah FS, Adinku MO, Ankomah K, Osei-Bonsu EB, Gyan KK, Altorki NK, Cheng E, Ginter PS, Hoda S, Newman L, Elemento O, Olopade OI, Davis MB, Martin ML, Bargonetti J. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Cancer Lett. 2024 03 01; 584:216608.
Score: 0.176
-
Wang J, Chang CY, Yang X, Zhou F, Liu J, Bargonetti J, Zhang L, Xie P, Feng Z, Hu W. p53 suppresses MHC class II presentation by intestinal epithelium to protect against radiation-induced gastrointestinal syndrome. Nat Commun. 2024 01 02; 15(1):137.
Score: 0.176
-
Abbas T, White D, Hui L, Yoshida K, Foster DA, Bargonetti J. Inhibition of human p53 basal transcription by down-regulation of protein kinase Cdelta. J Biol Chem. 2004 Mar 12; 279(11):9970-7.
Score: 0.176
-
Molina MP, Cain C, Bargonetti J. In vivo footprinting and DNA affinity chromatography for analysis of p53 DNA binding ability. Methods Mol Biol. 2003; 234:151-70.
Score: 0.164
-
Abbas T, Olivier M, Lopez J, Houser S, Xiao G, Kumar GS, Tomasz M, Bargonetti J. Differential activation of p53 by the various adducts of mitomycin C. J Biol Chem. 2002 Oct 25; 277(43):40513-9.
Score: 0.160
-
Wilson T, Pirovano G, Xiao G, Samuels Z, Roberts S, Viray T, Guru N, Zanzonico P, Gollub M, Pillarsetty NVK, Reiner T, Bargonetti J. PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models. Mol Pharm. 2021 09 06; 18(9):3418-3428.
Score: 0.148
-
Farooqi K, Ghazvini M, Pride LD, Mazzella L, White D, Pramanik A, Bargonetti J, Moore CW. A Protein in the Yeast Saccharomyces cerevisiae Presents DNA Binding Homology to the p53 Checkpoint Protein and Tumor Suppressor. Biomolecules. 2020 03 07; 10(3).
Score: 0.135
-
Gao C, Xiao G, Piersigilli A, Gou J, Ogunwobi O, Bargonetti J. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells. Breast Cancer Res. 2019 01 14; 21(1):5.
Score: 0.125
-
Pfister NT, Fomin V, Regunath K, Zhou JY, Zhou W, Silwal-Pandit L, Freed-Pastor WA, Laptenko O, Neo SP, Bargonetti J, Hoque M, Tian B, Gunaratne J, Engebraaten O, Manley JL, B?rresen-Dale AL, Neilsen PM, Prives C. Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes Dev. 2015 Jun 15; 29(12):1298-315.
Score: 0.097
-
Polotskaia A, Xiao G, Reynoso K, Martin C, Qiu WG, Hendrickson RC, Bargonetti J. Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4. Proc Natl Acad Sci U S A. 2015 Mar 17; 112(11):E1220-9.
Score: 0.095
-
Shi M, Shtraizent N, Polotskaia A, Bargonetti J, Matsui H. Impedimetric detection of mutant p53 biomarker-driven metastatic breast cancers under hyposmotic pressure. PLoS One. 2014; 9(6):e99351.
Score: 0.091
-
Rodriguez OC, Choudhury S, Kolukula V, Vietsch EE, Catania J, Preet A, Reynoso K, Bargonetti J, Wellstein A, Albanese C, Avantaggiati ML. Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy. Cell Cycle. 2012 Dec 01; 11(23):4436-46.
Score: 0.081
-
Freed-Pastor WA, Mizuno H, Zhao X, Langer?d A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, Bissell MJ, Osborne TF, Tian B, Lowe SW, Silva JM, B?rresen-Dale AL, Levine AJ, Bargonetti J, Prives C. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 2012 Jan 20; 148(1-2):244-58.
Score: 0.077
-
Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004 Nov 24; 119(5):591-602.
Score: 0.047
-
Hui L, Abbas T, Pielak RM, Joseph T, Bargonetti J, Foster DA. Phospholipase D elevates the level of MDM2 and suppresses DNA damage-induced increases in p53. Mol Cell Biol. 2004 Jul; 24(13):5677-86.
Score: 0.045